Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices

Drug Metabolism Reviews

Volumn 47, Issue 2, 2015, Pages 124-174

  Castaneto, Marisol S ^a,b   Wohlfarth, Ariane ^a   Desrosiers, Nathalie A ^a,b   Hartman, Rebecca L ^a,b   Gorelick, David A ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Analysis; GC MS; LC MS MS; Metabolite profiling; Methods; Novel psychoactive substances; Pharmacokinetics; Review; Synthetic cannabinoids

Indexed keywords

CANNABINOID DERIVATIVE; DRUG METABOLITE; CANNABINOID; STREET DRUG;

ADIPOSE TISSUE; ANALYTIC METHOD; BRAIN TISSUE; DEFLUORINATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HYDROXYLATION; DRUG TRANSFORMATION; GAS CHROMATOGRAPHY; HUMAN; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; ANIMAL; ANTIBODY SPECIFICITY; BIOTRANSFORMATION; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DEVICES; LIVER; METABOLISM; PROCEDURES; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANIMALS; BIOTRANSFORMATION; BRAIN; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; HUMANS; LIVER; MASS SPECTROMETRY; MOLECULAR STRUCTURE; ORGAN SPECIFICITY; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84932131181     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2015.1029635     Document Type: Review

References (128)

1. Adamowicz P, Zuba D, Sekula K. (2013). Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 233:320-327.
2. Amaratunga P, Thomas C, Lemberg BL, Lemberg D. (2014). Quantitative measurement of XLR11 and UR-144 in oral fluid by LC-MS-MS. J Anal Toxicol 38:315-321.
3. American Association of Poison Control Call Centers. (2014). Synthetic Marijuana Data: December 31, 2014. AAPCC. Available: https://aapcc.s3.amazonaws.com/files/library/Syn-Marijuana-Web-Data-Through-12.2014.pdf [last accessed 24 Jan 2014].
4. Ammann J, Mclaren JM, Gerostamoulos D, Beyer J. (2012). Detection and quantification of new designer drugs in human blood: Part 1-Synthetic cannabinoids. J Anal Toxicol 36:372-380.
5. Arnston A, Ofsa B, Lancaster D, et al. (2013). Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 37:284-290.
6. Barna I, Till I, Haller J. (2009). Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55, 212 and SR-141716A after their intraperitoneal injection in mice: Compound-specific and areaspecific distribution within the brain. Eur Neuropsychopharmacol 19:533-541.
7. Barnes AJ, Young S, Spinelli E, et al. (2014). Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Sci Int 241:27-34.
8. Beaulieu P, Rice ASC. (2002). The pharmacology of cannabinoid derivatives: Are there applications to treatment of pain?. Ann Fr Anesth Reanim 21:493-508.
9. Behonick G, Shanks KG, Firchau DJ, et al. (2014). Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38:559-562.
10. Beuck S, Moeller I, Thomas A, et al. (2011). Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Anal Bioanal Chem 401:493-505.
11. Castaneto MS, Desrosiers ND, Ellefsen K, et al. (2014). Method validation of the biochip array technology for synthetic cannabinoids detection in urine. Bioanalysis 6:2917-2928.
12. Castaneto MS, Gorelick DA, Desrosiers NA, et al. (2014). Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12-41.
13. Castaneto MS, Scheidweiler KB, Gandhi A, et al. (2014). Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal doi:10.1002/dta.1709.
14. Centers for Disease Control and Prevention. (2013). Acute kidney injury associated with synthetic cannabinoid use. Morb Mortal Wkly Rep 62:93-98.
15. Centers for Disease Control and Prevention. (2013). Notes from the field: Severe illness associated with synthetic cannabinoid use-Brunswick, GEORGIA, 2013. Morb Mortal Wkly Rep 62:939.
16. Chambers AP, Koopmans HS, Pittman QJ, Sharkey KA. (2006). AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol 147:109-116.
17. Chimalakonda KC, Bratton SM, Le VH, et al. (2011). Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 39: 1967-1976.
18. Chimalakonda KC, Moran CL, Kennedy PD, et al. (2011). Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem 83:6381-6388.
19. Chimalakonda KC, Seely KA, Bratton SM, et al. (2012). Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174-2184.
20. Coulter C, Garnier M, Moore C. (2011). Synthetic cannabinoids in oral fluid. J Anal Toxicol 35:424-430.
21. Crimele V, Klinger N, Etter M, et al. (2014). O21:Testing for 18 synthetic cannabinoid in hair using HPLC-MS/MS: Method development and validation, its application to authentic samples and preliminary results. Toxicol Anal Clin 26:S13.
22. De Brabanter N, Esposito S, Geldof L, et al. (2013). In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). Forensic Toxicol 31:212-222.
23. De Brabanter N, Esposito S, Tudela E, et al. (2013). In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27:2115-2126.
24. De Castro A, Pineiro B, Lendoiro E, et al. (2013). Quantification of selected synthetic cannabinoids and delta-9-Tetrahydrocannabinol in oral fluid by liquid chromatrography-Tandem mass spectrometry. J Chromatogr A 1295:99-106.
25. De Jager AD, Warner JV, Henman M, et al. (2012). LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine-An Australian perspective. J Chromatogr B Analyt Technol Biomed Life Sci 897:22-31.
26. Dowling G, Regan L. (2011). A method for CP74, 497 a synthetic nontraditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry. J Chrom B Analyt Technol Biomed Life Sci 879:253-259.
27. Dresen S, Kneisel S, Weinmann W, et al. (2011). Development and validation of a liquid chromatography-Tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 46:163-171.
28. Dziasdosz M, Weller JP, Klintschar M, et al. (2013). Scheduled multiple reaction monitoring algorithm as a way to analyse new designer drugs combined with synthetic cannabinoids in human serum with liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 929:84-89.
29. ElSohly MA, GulW, ElSohly KM, et al. (2011). Liquid chromatographytandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 35:487-495.
30. Finn DP, Chapman V. (2004). Cannabinoids as analgesic agents: Evidence from in vivo studies. Curr Neuropharmacol 2:75-89.
31. Fouda HG, Lukaszewicz J, Luther EW. (1987). Selected ion monitoring analysis of CP-55, 940, a cannabinoid derived analgetic agent. Biomed Environ Mass Spectrom 14:599-602.
32. Freeman MJ, Rose DZ, Myers MA, et al. (2013). Ischemic stroke after use of the synthetic marijuana spice. Neurology 81:2090-2093.
33. Freijo Jr TD, Harris SE, Kala SV. (2014). A rapid quantitative method for the analysis of synthetic cannabinoids by liquid chromatographytandem mass spectrometry. J Anal Toxicol 38:466-478.
34. Gambaro V, Arnoldi S, Bellucci S, et al. (2014). Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids. J Chromatogr B Analyt Technol Biomed Life Sci 957:68-76.
35. Gandhi AS, Wohlfarth A, Zhu M, et al. (2014). High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal 7:187-198.
36. Gandhi AS, Zhu M, Pang S, et al. (2013). First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15:1091-1098.
37. Gandhi AS, Zhu M, Pang S, et al. (2014). Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. Bioanalysis 6:1471-1485.
38. Gottardo R, Sorio D, Musile G, et al. (2013). Screening for synthetic cannabinoids in hair by using LC-QTOF MS: A new and powerful approach to study the penetration of these new psychoactive substances in the population. Med Sci Law 54:22-27.
39. Grigoryev A, Kavanagh P, Melnik A, et al. (2013). Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37: 265-276.
40. Grigoryev A, Kavanagh P, Melnik A. (2012). The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 4:519-524.
41. Grigoryev A, Kavanagh P, Melnik A. (2013). The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 5: 110-115.
42. Grigoryev A, Melnik A, Savchuk S, et al. (2011). Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 879:2519-2526.
43. Grigoryev A, Saychuk S, Melnik A, et al. (2011). Chromatographymass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 879: 1126-1136.
44. Guale F, Shahreza S, Walterscheid JP, et al. (2013). Validation of LCTOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 37:17-24.
45. Gugelmann H, Gerona R, Li C, et al. (2014). Crazy Monkey poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila) 52:635-638.
46. Gurney SMR, Scott KS, Kacinko SL, et al. (2014). Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26:53-78.
47. Harvey DJ. (1991). Metabolism and pharmacokinetics of the cannabinoids. Biochem Physiol Subst Abuse 3:279-365.
48. Heltsley R, Shelby MK, Crouch DJ, et al. (2012). Prevalence of synthetic cannabinoids in U.S. athletes: Initial findings. J Anal Toxicol 36: 588-593.
49. Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K. (2014). Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal 7:199-206.
50. Huppertz LM, Kneisel S, Auwarter V, Kempf J. (2014). A comprehensive library-based, automated screening procedure for 46 synthetic cannabinoids in serum employing liquid chromatography-quadrupole ion trap mass spectrometry with high-Temperature electrospray ionization. J Mass Spectrom 49:117-127.
51. Hutter M, Broecker S, Kneisel S, Auwarter V. (2012). Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in herbal mixtures using LC-MS/MS techniques. J Mass Spectrom 47:54-65.
52. Hutter M, Kneisel S, Auwarter V, Neukamm MA. (2012). Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 903:95-101.
53. Hutter M, Moosmann B, Kneisel S, Auwarter V. (2013). Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom 48:885-894.
54. Jang M, Shin I, Yang W, et al. (2014). Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 244:85-91.
55. Jang M, Shin I, Yang W, et al. (2014). Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int J Legal Med 128:285-294.
56. Jang M, Yang W, Choi H, et al. (2013). Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases. Forensic Sci Int 231:13-19.
57. Jenkins A. (2013). Forensic drug testing. In: Levine B (ed.) Principles of forensic toxicology. 4th ed. Washington (DC): AACC Press, 31-47.
58. Kacinko SL, Xu A, Homan JW, et al. (2011). Development and validation of a liquid chromatography tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 35:386-393.
59. Kavanagh P, Grigoryev A, Melnik A, Simonov A. (2012). The identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatography-mass spectrometry. J Anal Toxicol 36:303-311.
60. Kikura-Hanajiri R, Kawamura M, Shoda T, et al. (2011). Determination of synthetic cannabinoid JWH-018 and its metabolites in rat urine and hair samples using UPLC-MS/MS. Joint Meeting of the Society of Forensic Toxicologist and The International Association of Forensic Toxicologists, 25 September 2011, San Franscisco, CA.
61. Kim J, In S, Park Y, et al. (2013). Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation. Anal Bioanal Chem 405:9769-9778.
62. Kim J, Park Y, Park M, et al. (2014). Simultaneous determination of five naphthoylindole-based synthetic cannabinoids and metabolites and their deposition in human and rat hair. J Pharm Biomed Anal 102: 162-175.
63. Kneisel S, Auwarter V, Kempf J. (2012). Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test Anal 5:657-669.
64. Kneisel S, Auwarter V. (2012). Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 47: 825-835.
65. Kneisel S, Speck M, Moosmann B, Auwarter V. (2013). Stability of 11 prevalent synthetic cannabinoids in authentic neat oral fluid samples: Glass versus polypropylene containers at different temperatures. Drug Test Anal 5:602-606.
66. Kneisel S, Speck M, Moosmann B, et al. (2013). LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal Bioanal Chem 405:4691-4706.
67. Kneisel S, Teske J, Auwarter V. (2014). Analysis of synthetic cannabinoids in abstinence control: Long drug detection windows in serum and implications for practitioners. Drug Test Anal 6:135-136.
68. Kramer T, Meyer M, Wissenbach D, et al. (2008) Studies on the metabolism of JWH-018, the pharmacologically active ingredient of different misused incenses (V10). Society of Toxiocological and Forensic Chemistry Conference, Germany.
69. Kronstrand R, Brinkhagen L, Birath-Karlsson C, et al. (2014). LCQTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal Bioanal Chem 405:3599-3609.
70. Kronstrand R, Roman M, Andersson M, et al. (2013). Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 37:534-541.
71. Logan BK, Reinhold LE, Kacinko SL. (2011). K2 and Beyond: A Synthetic Cannabinoid Primer (K43). American Academy of Forensic Sciences, 2011 Feb 21-26, Chicago, IL.
72. Lovett DP, Yanes EG, Herbelin TW, et al. (2013). Structure elucidation and identification of a common metabolite for napthoylindole-based synthetic cannabinoids using LC-TOF and comparison to a synthetic reference standard. Forens Sci Int 226:81-87.
73. Mazzarino M, De La Torre X, Botre F. (2014). A liquid chromatographymass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. Anal Chim Acta 837:70-82.
74. McQuade D, Hudson S, Dargan PI, et al. (2013). First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69: 373-376.
75. Mir A, Obafemi A, Young A, Kane C. (2011). Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128: e1622-e1627.
76. Mohr AL, Ofsa B, Keil AM, et al. (2014). Enzyme-linked immunosorbent assay (ELISA) for the detection of use of the synthetic cannabinoid agonists UR-144 and XLR-11 in human urine. J Anal Toxicol 38:427-431.
77. Moller I, Wintermeyer A, Bender K, et al. (2011). Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 9:606-620.
78. Moore C, Coulter C, Uges D, et al. (2011). Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci Int 212: 227-230.
79. Moran CL, Le VH, Chimalakonda KC, et al. (2011). Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228-4236.
80. Oiestad E, Johansen U, Christophersen A, Karinen R. (2013). Screening of synthetic cannabinoids in preserved oral fluid by UPLC-MS/MS. Bioanalysis 5:2257-2268.
81. Papanti D, Schifano F, Botteon G, et al. (2013). Spiceophrenia: A systematic overview of Spice-related psychopathological issues and a case report. Hum Psychopharmacol 28:379-389.
82. Patton AL, Chimalakonda KC, Moran CL, et al. (2013). K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58:1676-1680.
83. Patton AL, Seely KA, Chimalakonda KC, et al. (2013). Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem 85:9390-9399.
84. Poklis JL, Amira D, Wise LE, et al. (2012). Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to buzz smoke by HPLC/MS/MS. Biomed Chromatogr 26:1393-1398.
85. Poklis JL, Amira D, Wise LE, et al. (2012). Detection and disposition of JWH-018 and JWH-073 in mice after exposure to Magic Gold smoke. Forensic Sci Int 220:91-96.
86. Presley BC, Jansen-Varnum SA, Logan BK. (2013). Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Sci Rev 25:27-46.
87. Regan SL, Maggs JL, Hammond TG, et al. (2010). Acyl glucuronides: The good, the bad and the ugly. Biopharm Drug Dispos 31:367-395.
88. Rodrigues WC, Catbagan P, Rana S, et al. (2013). Detection of synthetic cannabinoids in oral fluid using ELISA and LC-MS-MS. J Anal Toxicol 37:526-533.
89. Salomone A, Gerace E, D'Urso F, et al. (2012). Simultaneous analysis of several synthetic cannabinoids, THC, CBD and CBN, in hair by ultrahigh performance liquid chromatography tandem mass spectrometry: Method validation and application to real samples. J Mass Spectrom 47:604-610.
90. Salomone A, Gerace E, Luciano C, et al. (2014). O22:Quantification of 22 synthetic cannabinoids and 10 metabolites in human hair. Toxicol Analyt Clin 26:S14.
91. Salomone A, Luciano C, Di Corcia D, et al. (2014). Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers. Drug Test Anal 6:126-134.
92. Schaefer N, Peters B, Bregel D, et al. (2014). Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats?. Biomed Chromatogr 28:1043-1047.
93. Scheidweiler KB, Huestis, MA. (2014). Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-Tandem mass spectrometry. J Chromatogr A 1327:105-117.
94. Scheidweiler KB, Jarvis MJ, Huestis, MA. (2014). Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem 407:883-897.
95. Schep L, Slaughter R, Hudson S, et al. (2014). Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoids analogues. Hum Exp Toxicol. doi:10.1177/0960327114550886.
96. Shanks KG, Dahn T, Terrell AR. (2012). Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 36:145-152.
97. Simoes SS, Silva I, Ajenjo AC, et al. (2014). Validation and application of an UPLC-MS/MS method for the quantification of synthetic cannabinoids in urine samples and analysis of seized materials from the Portugues market. Forensic Sci Int 243:117-125.
98. Smeal SJ (2007). The incorporation of delta-9-Tetrahydrocannabinol and its metabolite, 11-nor-carboxy-delta-9-Tetrahydrocannabinol, into hair. PhD Thesis. Salt Lake City (UT): University of Utah.
99. Sobolevsky T, Prasolov I, Rodchenkov G. (2012). Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745-753.
100. Sobolevsky T, Prasolov I, Rodchenvkov G. (2010). Detection of JWH-018 metabolites in smoking mixture post-Administration urine. Forensic Sci Int 200:141-147.
101. Spinelli E, Barnes AJ, Young S, et al. (2014). Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Drug Test Anal. doi:10.1002/dta.1702.
102. Strano-Rossi S, Anzillotti L, Castrignano E, et al. (2012). Ultra high performance liquid chromatography-electrospray ionization-Tandem mass spectrometry screening method for direct analysis of designer drugs, spice and stimulants in oral fluid. J Chromatogr A 1258:37-42.
103. Strano-Rossi S, Anzillotti L, Dragoni S, et al. (2014). Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: A pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal Bioanal Chem 406:3621-3636.
104. Sundstrom M, Pelander A, Angerer V, et al. (2013). A high-sensitivity ultra-high performance liquid chromatography/high-resolution timeof-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 405:8463-8474.
105. Takayama T, Suzuki M, Todoroki K, et al. (2014). UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5FQUPIC and alpha-PVT, by human liver microsome. Biomed Chromatogr 28:831-838.
106. Teske J, Weller J-P, Fieguth A, et al. (2010). Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-Tandem mass spectrometry. J Chromatog B Analyt Technol Biomed Life Sci 878:2659-2663.
107. Thomas BF, Martin BR. (1990). In vitro metabolism of (-)-cis-3-[2-hydroxy-4-(1, 1-dimethylheptyl)phenyl]-Trans-4-(3-hydroxypropyl) cyclohexanol, a synthetic bicyclic cannabinoid analog. Drug Metab Dispos 18:1046-1054.
108. Tuv SS, Krabseth H, Karinen R, et al. (2014). Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev 62: 26-31.
109. Uhelski ML, Khasabova IA, Simone DA. (2014). Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. J Neurophysiol 113:1501-1510.
110. Uhl M, Sachs H. (2004). Cannabinoids in hair: Strategy to prove marijuana/hashish consumption. Forensic Sci Int 145:143-147.
111. United Nations Office on Drugs and Crime. (2011). Synthetic Cannabinoids in Herbal Products. Available from: http://www.unodc.org/unodc/en/scientists/synthetic-cannabinoids-in-herbal-products.html [last accessed 15 Sept 2014].
112. United Nations on Drugs and Crime. (2014). World Drug Report 2014. Available at: http://www.unodc.org/wdr2014/[last accessed 15 Jan 2015].
113. US Drug Enforcement Administration. (2013). Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664-666.
114. US Drug Enforcement Administration. (2013). Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into Schedule I. Final order. Fed Regist 78:28735-28739.
115. US Drug Enforcement Administration. (2014). Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I: Notice of Intent. Fed Regist 79:7577-7582.
116. Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. (2004). Transdermal delivery of the synthetic cannabinoid WIN 55, 212-2: In vitro/in vivo correlation. Pharm Res 21:1137-1145.
117. Valiveti S, Kiptoo PK, Hammell DC, Stinchcomb AL. (2004). Transdermal permeation of WIN 55, 212-2 and CP 55, 940 in human skin in vitro. Int J Pharm 278:173-180.
118. Wintermeyer A, Moller I, Thevis M, et al. (2010). In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141-2153.
119. Wohlfarth A, Gandhi AS, Pang S, et al. (2014). Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763-1780.
120. Wohlfarth A, Pang S, Zhu M, et al. (2013). First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59: 1638-1648.
121. Wohlfarth A, Pang S, Zhu M, et al. (2014). Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6:1187-1200.
122. Wohlfarth A, Scheidweiler KB, Castaneto M, et al. (2014). Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clin Chem Lab Med 53:423-434.
123. Wohlfarth A, Scheidweiler KB, Chen X, et al. (2013). Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 85: 3730-3738.
124. World Anti-Doping Agency. (2014). The 2014 Prohibited List International Standard. Available from: http://www.wada-Ama.org/Documents/World-Anti-Doping-Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf [last accessed 15 Jan 2014].
125. Yanes EG, Lovett DP. (2012). High-Throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using saltingout sample preparation and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 909:42-50.
126. Yeakel JK, Logan BK. (2013). Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol 37: 547-551.
127. Zhang Q, Ma P, Cole RB, Wang, G. (2006). Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal Bioanal Chem 386:1345-1355.
128. Zhang Q, Ma P, Iszard M, et al. (2002). In vitro metabolism of R(+)-[2, 3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1, 2, 3-de]1, 4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos 30:1077-1086